Enhancement of amlodipine cardioprotection by quercetin in ischaemia/reperfusion injury in rats

Journal of Pharmacy and Pharmacology

Volumn 61, Issue 9, 2009, Pages 1233-1241

  Ahmed, Lamiaa A ^a   Salem, Hesham A ^a   Attia, Amina S ^a   El Sayed, Mostafa E ^a  

^a CAIRO UNIVERSITY   (Egypt)

Author keywords

Amlodipine; Arrhythmias; Ischaemia; Quercetin; Reperfusion

Indexed keywords

AMLODIPINE; CREATINE KINASE; GLUTATHIONE; LACTIC ACID; MYELOPEROXIDASE; NITRATE; NITRITE; POLYSORBATE 80; QUERCETIN; THIOBARBITURIC ACID REACTIVE SUBSTANCE; ANTIOXIDANT; CARDIOTONIC AGENT; VASODILATOR AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL PROTECTION; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; DRUG EFFICACY; HEART; HEART MUSCLE CELL; HEART MUSCLE ISCHEMIA; HEART PROTECTION; HEART RATE; HEART VENTRICLE ARRHYTHMIA; HISTOLOGY; LACTATE BLOOD LEVEL; MALE; MONOTHERAPY; NONHUMAN; RAT; REPERFUSION INJURY; ANIMAL; DRUG COMBINATION; DRUG EFFECT; DRUG SCREENING; HEART ARRHYTHMIA; HEART VENTRICLE; METABOLISM; PATHOLOGY; RANDOMIZATION;

AMLODIPINE; ANIMALS; ANTIOXIDANTS; ARRHYTHMIAS, CARDIAC; CARDIOTONIC AGENTS; DRUG EVALUATION, PRECLINICAL; DRUG THERAPY, COMBINATION; HEART RATE; HEART VENTRICLES; MALE; MYOCARDIAL REPERFUSION INJURY; QUERCETIN; RANDOM ALLOCATION; RATS; VASODILATOR AGENTS;

EID: 85047683736     PISSN: 00223573     EISSN: None     Source Type: Journal    
DOI: 10.1211/jpp.61.09.0014     Document Type: Article

References (51)

1. Becker BF, Möbert J. Low-dose calcium antagonists reduce energy demand and cellular damage of isolated hearts during both ischemia and reperfusion. Naunyn-Schmiedeberg's Arch Pharmacol 1999; 360: 287-294.
2. Chen JK, Chow SE. Antioxidants and myocardial ischemia: reperfusion injuries. Chang Gung Med J 2005; 28: 369-377.
3. Sahna E et al. Protective effects of melatonin on myocardial ischemia-reperfusion induced infarct size and oxidative changes. Physiol Res 2005; 54: 491-495.
4. Piper HM et al. Cellular mechanisms of ischemia-reperfusion injury. Ann Thorac Surg 2003; 75: 644-648.
5. Opie LH. First line drugs in chronic stable effort angina. The case for newer, longer-acting calcium channel blocking agents. Am Coll Cardiol 2000; 36: 1967-1971.
6. Stepien O et al. Amlodipine inhibition of serum thrombin or fibroblast growth factor-induced vascular smooth muscle cell proliferation. J Cardiovasc Pharmacol 1998; 31: 786-793.
7. Phillips JE, Mason RP. Inhibition of oxidized LDL aggregation with a charged calcium antagonist amlodipine: role of electrostatic interactions. Atherosclerosis 2003; 168: 239-244.
8. Champagne S et al. Reduced coronary vasodilator responses to amlodipine in pacing induced heart failure in conscious dogs: role of nitric oxide. Br J Pharmacol 2002; 136: 264-270.
9. Lakhanpal P, Rai DK. Quercetin: a versatile flavonoid. Internet Journal of Medical Update 2007; 2: 1-16.
10. Sorata Y et al. Protective effect of quercetin and rutin on photosensitized lysis of human erythrocytes in the presence of hematoporphyrin. Biochim Biophys Acta 1984; 799: 313-317.
11. Ferrali M et al. Protection against oxidative damage of erythrocyte membrane by the flavonoid quercetin and its relation to iron chelating activity. FEBS Lett 1997; 416: 123-129.
12. Morel I et al. Antioxidant and iron chelating activities of the flavonoids catechin, quercetin and diosmetin on iron-loaded rat hepatocyte cultures. Biochem Pharmacol 1993; 45: 13-19.
13. Shoskes DA. Effect of bioflavonoids quercetin and curcumin on ischemic renal injury: a new class of renoprotective agents. Transplantation 1998; 66: 147-152.
14. Dow JS et al. Can moderate alcohol intake limit the size of myocardial infarction? Cardiovasc Pharmacol 2001; 37: 662-667.
15. Walker MJA et al. The Lambeth Conventions: guidelines for the study of arrhythmias in ischaemia infarction, and reperfusion. Cardiovasc Res 1988; 22: 447-455.
16. Curtis MJ, Walker MJA. Quantification of arrhythmias using scoring systems: an examination of seven scores in an in vivo model of regional ischaemia. Cardiovasc Res 1988; 22: 656-665.
17. Noll F. L-(+)-Lactate. In: Bergmeyer HU, ed. Methods of Enzymatic Analysis, 3rd edn. VCH-Verlagsgesellschaft, Weinheim, Germany, 1985: 582-588.
18. Lowry OH et al. Effect of ischemia on known substances and cofactors of the glycolytic pathways in brain. Biol Chem 1964; 239: 18-30.
19. Uchiyama M, Mihara M. Determination of malondialdehyde precursor in tissue by thiobarbituric acid test. Anal Biochem 1978; 86: 271-278.
20. Beutler E et al. Improved method for the determination of blood glutathione. Lab Clin Med 1963; 61: 882-888.
21. Bradley PP et al. Measurement of cutaneous inflammation: estimation of neutrophil content with an enzyme marker. Invest Dermatol 1982; 78: 206-209.
22. Miranda KM et al. A rapid, simple spectrophotometric method for simultaneous detection of nitrate and nitrite. Nitric oxide Biol Chem 2001; 5: 62-71.
23. Houle MS, Billman GE. Low frequency component of heart rate variability spectrum: a poor marker of sympathetic activity. Am J Physiol Heart Circ Physiol 1999; 276: 215-223.
24. Thaulow E et al. Role of calcium channel blockers in experimental excerise-induced ischemia. Cardiovasc Drugs Ther 1988; 1: 503-512.
25. Ravingerova T et al. Ventricular arrhythmias following coronary artery occlusion in rats: is the diabetic heart less or more sensitive to ischemia? Basic Res Cardiol 2001; 96: 160-168.
26. Kajiwara H et al. Effects of a novel cyclohexane dicarboximide derivative, ST-6, on reperfusion-induced arrhythmia in rats. Pharmacol Sci 2005; 98: 8-15.
27. Manning AS, Hearse DJ. Reperfusion-induced arrhythmias: mechanisms and prevention. Mol Cell Cardiol 1984; 16: 497-518.
28. Zipes DP. Mechanisms of clinical arrhythmias. J Cardiovasc Electrophysiol 2003; 14: 902-912.
29. Vatner SF et al. Effects of calcium channel blocker on the response of blood flow, function, arrhythmias and extent of infarction following reperfusion in conscious baboons. Circ Res 1988; 62: 105-115.
30. Swies J et al. Occlusion and reperfusion-induced arrhythmias in rats: involvement of platelets and effects of calcium antagonists. J Cardiovasc Pharmacol 1990; 15: 816-825.
31. Timour Q et al. Delay by a calcium antagonist, amlodipine, of the onset of primary ventricular fibrillation in myocardial ischemia. Cardiovasc Drugs and Therapy 1996; 10: 447-454.
32. Ishikawa Y et al. Reversible myocardial ischemic injury is not associated with increased creatine kinase activity in plasma. Clin Chem 1997; 43: 467-475.
33. Gustafsson AB, Gottlieb RA. Heart mitochondria: gates of life and death. Cardiovasc Res 2007; 5: 1-10.
34. Cairns CB et al. Postischemic administration of succinate reverses the impairment of oxidative phosphorylation after cardiac ischemia and reperfusion injury. Circulation 1997; 96: 260-265.
35. Mitra B, Panja M. Myocardial metabolism: pharmacological manipulation in myocardial ischemia. J Assoc Phys India 2005; 53: 552-560.
36. Solaini G, Harris DA. Biochemical dysfunction in heart mitochondria exposed to ischaemia and reperfusion. Biochem J 2005; 390: 377-394.
37. Jennings RB et al. Effect of inhibition of the mitochondrial ATPase on net myocardial ATP in total ischemia. Mol Cell Cardiol 1991; 23: 1383-1395.
38. McCarty MF. CoenzymeQ versus hypertension: does CoQ decrease endothelial superoxide generation? Med Hypotheses 1999; 53: 300-304.
39. Sestili P et al. Quercetin prevents DNA single strand breakage and cytotoxicity caused by tert-butylhydroperoxide: free radical scavenging versus iron chelating mechanism. Free Radic Biol Med 1998; 25: 196-200.
40. Cheng IF, Breen K. On the ability of four flavonoids, baicilein, luteolin, naringenin and quercetin to suppress the Fenton reaction of the iron-ATP complex. Biometals 2000; 13: 77-83.
41. Guzy J et al. Effect of quercetin on daunorubicin-induced heart mitochondria changes in rats. Physiol Res 2003; 52: 773-780.
42. Ambrosio G et al. Oxygen radicals generated at reflow induce peroxidation of membrane lipids in reperfused hearts. Clin Invest 1991; 87: 2056-2066.
43. Zweier JL et al. Direct measurement of free radical generation following reperfusion of ischemic myocardium. Proc Natl Acad Sci 1987; 84: 1404-1407.
44. Mason RP et al. Membrane antioxidant effects of the charged dihydropyridine calcium antagonist amlodipine. Mol Cell Cardiol 1999; 31: 275-281.
45. Hoshida S et al. Reduction in infarct size by chronic amlodipine treatment in cholesterol-fed rabbits. Atherosclerosis 1998; 138: 163-170.
46. Mollace V et al. Nitric oxide from vascular smooth cells: regulation of platelet reactivity and smooth muscle cell guanylate cyclase. Br J Pharmacol 1991; 104: 633-638.
47. Zweier JL, Talukder MAH. The role of oxidants and free radicals in reperfusion injury. Cardiovasc Res 2006; 70: 181-190. 48. Ambrosio G, Tritto I. Myocardial reperfusion injury. Eur Heart J 2002; 4: 28-30.
48. Siragy HM et al. Beneficial effect of combined benazepril-amlodipine on cardiac nitric oxide, cGMP and TNF-α production after cardiac ischemia. Cardiovasc Pharmacol 2006; 47: 636-642.
49. Kobayashi N et al. Effects of amlodipine on nitric oxide synthase mRNA expression and coronary microcirculation in prolonged nitric oxide blockade-induced hypertensive rats. Cardiovasc Pharmacol 1999; 34: 173-181.
50. Dias AS et al. Quercetin decreases oxidative stress, NF-κB activation and iNOS overexpression in liver of streptozotocin-induced diabetic rats. Nutrition 2005; 135: 2299-2304.
51. Jackson SJT, Venema RC. Quercetin inhibits eNOS, microtubule polymerization and mitotic progression in bovine aortic endothelial cells. Nutrition 2006; 136: 1178-1184.